RARG and esophageal squamous cell carcinoma: Additionally, our study found that CD2665, one of the RARγ antagonist, inhibited TNFAIP3 expression in ESCC‐TRCs, indicating that TNFAIP3 may function as a downstream target regulated by RARγ.